St. Jude Biocor Would Capitalize On Broad Stented Tissue Valve Market
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical plans to launch four new tissue mitral valves in the U.S. in the third quarter of 2005, including the Biocor stented porcine valve
You may also be interested in...
St. Jude Enters $350 Mil. U.S. Stented Tissue Valve Market With Biocor
St. Jude Medical expects to reverse the long decline of its heart valve sales in the second half of 2005 with FDA approval of the Biocor stented tissue valves, announced Aug 8
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.